Please use this identifier to cite or link to this item:
http://localhost:8080/xmlui/handle/123456789/6302
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Costello, Rebecca | - |
dc.contributor.author | Rosanoff, Andrea | - |
dc.contributor.author | Nielsen, Forrest | - |
dc.contributor.author | West, Christina | - |
dc.date.accessioned | 2024-09-25T01:50:02Z | - |
dc.date.available | 2024-09-25T01:50:02Z | - |
dc.date.issued | 2023-07-23 | - |
dc.identifier.uri | http://localhost:8080/xmlui/handle/123456789/6302 | - |
dc.description.abstract | ABSTRACT In 1997, the US Institute of Medicine (IOM) dietary reference intakes (DRI) Committee established a magnesium (Mg) tolerable upper intake level (UL) for adults of 350 mg/d from supplemental intake alone. Diarrhea was the limiting factor. The safety of oral Mg dietary supplements exceeding the UL is currently in debate. Increasing the UL may result in more Mg supplementation, decreasing the prevalence of undernutrition for this nutrient and thus providing additional protection against numerous chronic diseases. This perspective aims to show that more recent and comprehensive evidence-based data on the occurrence of diarrhea indicate that the Mg UL for adults should be reevaluated. To update the literature base to re-evaluate setting the Mg UL, a PubMed search was conducted to identify intervention studies published between 1997 and 2022 that used single-ingredient Mg products reporting a priori diarrhea adverse events among adults. The Food and Drug Administration Center for Food Safety and Adverse Event Reporting System (CAERS) was also searched for adverse events caused by Mg supplementation. The PubMed search identified 10 studies, including 5 meta-analyses and 5 randomized controlled trials, that met the search criteria. Seven studies (Mg intakes of 128–1200 mg/d) found no significant differences in diarrhea occurrence between the intervention and control groups. One meta-analysis found only minor differences in gastrointestinal disturbances between groups given placebo versus 520 mg Mg/d, but withdrawals were not significantly different between groups. Another meta-analysis found that 3 of 13 studies (120–973 mg/d) reported diarrhea that led to study withdrawal, but the treatment arm was not specified in 2 studies. The CAERS search, when limited to single-ingredient suspect Mg products, found only 40 attributable cases of gastrointestinal adverse events. Only one-third of these 40 cases noted a complaint of diarrhea. These updated data indicate that doses above the current UL for Mg supplements can be consumed without adverse events. Keywords: magnesium, diarrhea, adverse events, tolerable upper intake level, supplements | en_US |
dc.language.iso | en | en_US |
dc.publisher | Advances in Nutrition | en_US |
dc.subject | magnesium, | en_US |
dc.subject | diarrhea, | en_US |
dc.subject | adverse events, | en_US |
dc.subject | tolerable upper intake level, | en_US |
dc.subject | supplements | en_US |
dc.title | Perspective: Call for Re-evaluation of the Tolerable Upper Intake Level for Magnesium Supplementation in Adults | en_US |
dc.type | Article | en_US |
Appears in Collections: | VOL 14 No 5 2023 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
3. Perspective--Call-for-Re-evaluation-of-the-Tolerab.pdf | 471.96 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.